Full data from Alnylam's pivotal givosiran programme show a big impact for severe patients, though a case still needs to be made for a broader population.
A look at the abstract on Intercept’s Regenerate trial seems to confirm the earlier topline result, ahead of a full data presentation later today.
The group follows licensing deals with Dainippon and Roivant with a pivotal study win.
The industry’s most advanced oncolytic virus project, Pexa-Vec, faces a make-or-break pivotal study readout.
Questions about Akebia's disclosure of liver toxicity in a trial raise a red flag over vadadustat, the company's experimental anaemia treatment.
After two checkpoint combo trials flopped last month Syndax celebrates an unexpected win in a third.
Filgotinib could be the safest Jak inhibitor yet, but Galapagos will need to make the most of this as it squares up to Abbvie.
Rivipansel needs to help sickle cell patients leave hospital sooner and BCX7353 faces established hereditary angioedema agents.
A phase III failure will do nothing to help Supernus’s SPN-812 compete against generic ADHD drugs.